We would love to hear your thoughts about our site and services, please take our survey here.
11 October 2021
All Star Minerals Plc
("All Star" or the "Company")
Non-Executive Chairman Retirement
All Star (AQSE:ASMO) announces the retirement of Mr Graham Mascall from the Board with immediate effect.
The decision has been made for personal reasons, and a desire on the part of Mr Mascall to focus his attentions on family matters.
Interim CEO, Ian Harebottle, said:
"It is with regret that we announce the retirement of Graham from the Board, but his reasons and motivations are appreciated and fully understood. Graham's considerable experience, input and dedication to the Company and all of its shareholders during his tenure, will be sorely missed. We will be initiating a search for All Star Minerals new chairman, in due course."
https://www.**********.co.uk/rns/announcement/ff2276fc-2ab7-4f2b-a8f8-4c1cde28a767/
The best one to compare GCAT is US listed Tanzania gold Corp.
It's market cap is North of $100m+ and they have a project at feasibility and a refractory project - tough xmetallurgy and processing - and have 50% of a very low grade ore body in Tanzania.
Anyone up for it doing a comparison.
Your findings should then show we look very very cheap and excellent value at this stage...
Long time fella. Hope you are well.
The best one to compare GCAT is US listed Tanzania gold Corp.
It's market cap is North of $100m+ and they have a project at feasibility and a refractory project - tough xmetallurgy and processing - and have 50% of a very low grade ore body in Tanzania.
Anyone up for it doing a comparison.
Your findings should then show we look very very cheap and excellent value at this stage...
So you know how to read buy's and sell's...
Yet you never comment positively about anything, amazing that we have increased 45% since June and you can't find a single word of support.
So you know how to read buy's and sell's...
Yet you never comment positively about anything, amazing that we have increased 45% since June and you can't find a single word of support.
Never fully understand the negativity of some posters and their continual bashing of the company and their investment...
Taking all things into consideration, they must not be invested in the longer term prospects of Truspine and trading it...
About time you guys moved on as you clearly have no real interest and like to spam this board...
Csn we change the topic or tune... Its getting tiresome...
All buys today and Aquis have a live price now via Jarvis XO...
I do read some rubbish from the resident debbies... D250, you have the patience of a Saint...
Maybe the debbies will realise one day why they were not added to the telegram grp...
All have a gd day as we are up 35% since June...
F16 - Superb post that reflects the truspine ethos and reasons why we support the company... In all honesty mm's games or price manipulation are neither her or there... Majority of the legacy and new investors are behind the company...
One of the most undervalued companies I have researched..
10p+ inbound for the those worried on price...
TruSpine Technologies plc
("TruSpine" or the "Company")
Survey of Cervi-LOK™
TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its proprietary, pioneering "screwless," spinal (vertebral) stabilisation system, announces that its cornerstone Cervi-LOK™ device has completed Round II testing.
Round II testing consisted of a cadaver study which was conducted at the Upstate Medical School in Syracuse, New York, and was performed by two highly experienced surgeons who are also members of TruSpine's medical advisory board: Dr. Mark Smith / Neurosurgeon (tested on May 6) and Dr. William Lavelle / Orthopaedic spine surgeon (tested on May 7). Also in attendance was Nathan Erickson, the Lead Engineer from TruSpine's engineering partner, LincoTek, Inc., as well as Professor Frank Boehm, TruSpine's Chief Technical Consultant.
The objectives of the cadaver study included evaluating the usability of the instruments to implant the system, as well ease of insertion, grasp of the vertebrae and strength of the implant system. The surgeons conducted their study independent of one another, further enhancing the validity of the evaluation. The procedures were recorded on video, and pending editing, this should be available for general viewing on the TruSpine website in due course.
A stabilisation from the C2 to C5 vertebrae was achieved, on average in less than 15 minutes; in one instance, a unilateral stabilisation was achieved in 14 minutes from the time of the initial skin incision until the time of complete insertion of the implant, which is an exceptional outcome relative to current technologies as detailed below, even for a highly skilled surgeon.
No X-Rays were required, no injury to the bone was noted, and - as further confirmation of the benefits of the system, there was no possibility of injury to vascular or neurologic structures. This is in contrast to current technology, which can take 30 to 45 minutes or longer, requires significant intraoperative X-Rays, and can be complicated by injuries to critical blood vessels, nerves or even the spinal cord.
Dr. Smith was particularly impressed with the versatility and flexibility of the device and Dr. Lavelle thought that the system was excellent, noting some additional indications beyond those originally stated.
The overall view of both participating surgeons was that the system was extremely effective, efficient and has a great deal of appeal to practicing surgeons, with ease and convenience and avoidance of injury to critical structures. In addition, the Cervi-LOK™ system was highly praised for its flexibility and versatility and it was mutually agreed that the potential for commercial success was high.
Ian Roberts, CEO of TruSpine Technologies plc, commented: "We are delighted to receive this compelling feedback on the Cervi-LOK™ system by highly experienced surgeons. Both surgeons involve
Investegate |TruSpine Technolgs. Announcements | TruSpine Technolgs.: Further re Subscription
https://www.investegate.co.uk/truspine-technolgs.--tsp-/rns/further-re-subscription/202105250700066499Z/